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Background.  Acute cardiac events (ACEs) are increasingly being recognized as a major complication in pneumococcal 
community-acquired pneumonia (CAP). Information regarding host- and pathogen-related factors for ACEs, including pneumo-
coccal serotypes and clonal complexes, is scarce.
Methods.  A retrospective study was conducted of a prospective cohort of patients hospitalized for CAP between 1996 and 
2019. Logistic regression and funnel plot analyses were performed to determine host- and pathogen-related factors for ACEs.
Results.  Of 1739 episodes of pneumococcal CAP, 1 or more ACEs occurred in 304 (17.5%) patients, the most frequent being 
arrhythmia (n = 207), heart failure (n = 135), and myocardial infarction (n = 23). The majority of ACEs (73.4%) occurred within 
48 hours of admission. Factors independently associated with ACEs were older age, preexisting heart conditions, pneumococcal 
bacteremia, septic shock at admission, and high-risk pneumonia. Among 983 pneumococcal isolates, 872 (88.7%) were serotyped 
and 742 (75.5%) genotyped. The funnel plot analyses did not find any statistically significant association between serotypes or clonal 
complexes with ACEs. Nevertheless, there was a trend toward an association between CC230 and these complications. ACEs were 
independently associated with 30-day mortality (adjusted odds ratio, 1.88; 95% CI, 1.11–3.13).
Conclusions.  ACEs are frequent in pneumococcal pneumonia and are associated with increased mortality. The risk factors 
defined in this study may help identify patients who must undergo close follow-up, including heart rhythm monitoring, and special 
care to avoid fluid overload, particularly during the first 48 hours of admission. These high-risk patients should be the target for pre-
ventive intervention strategies.
Keywords.  acute cardiac events; community-acquired pneumonia; genotype; pneumococcal pneumonia; serotype.
Acute cardiac events pose a significant challenge in the man-
agement of community-acquired pneumonia (CAP) [1–3]. The 
incidence of acute cardiac events during the course of hospital-
ization for CAP ranges from 8% to 32% [4–7]. It is increasingly 
being recognized that the development of acute cardiac events 
in patients with CAP is an independent predictor of poor out-
comes [5, 7]. Moreover, hospitalized patients with CAP have 
a 2-fold increase in the long-term risk for cardiovascular dis-
ease, new-onset heart failure, and mortality compared with the 
general population [8–11].
Several cohort studies focusing on the overall population of 
all-cause CAP have identified certain host factors associated 
with the development of acute cardiac events [4–7, 12, 13]. 
Importantly, the development of life-threatening acute cardiac 
events appears to be particularly frequent among patients with 
pneumococcal CAP [4, 14]. The first study linking acute car-
diac events and pneumococcal pneumonia was carried out by 
Musher and colleagues in 2007 [15]. However, that seminal 
study reported only 33 cardiac events occurring in 170 patients, 
precluding an analysis of risk factors. Other researchers have 
found that pneumococcal bacteremia significantly increased 
the risk of new-onset heart failure up to 10  years after CAP 
compared with controls [9].
Interestingly, recent animal experimental models have shown 
that Streptococcus pneumoniae is capable of invading the my-
ocardium and inducing cardiac injury by promoting the for-
mation of microlesions [16–18]. In these studies, bacteremia 
strongly correlated with increasing levels of cardiac troponin-L 
and cardiac damage [19, 20]. Pneumolysin, a major virulence 
factor of S. pneumoniae, mediates cardiac damage and depresses 
cardiomyocyte contractile function [19, 21]. Antimicrobial 
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treatment has been associated with cardiac scarring as a result of 
collagen synthesis in damaged myocardium, which may explain 
the increased risk for long-term cardiac complications in hu-
mans due to the promotion of arrhythmias and/or impairment 
of left ventricular function [16, 17]. A recent experimental study 
in a small sample of mice found that cardiac damage is prob-
ably dependent on the ability of certain pneumococci to cause 
high-grade bacteremia and that the type of lesions might be 
strain-specific [20]. Interestingly, similar cardiac microlesions 
largely devoid of bacteria were observed in heart sections from 
3 rhesus macaques infected with simian immunodeficiency 
virus that died of pneumococcal pneumonia despite antibiotic 
therapy, and in 2 out of 9 humans who succumbed to invasive 
pneumococcal disease [17].
To date, however, no clinical studies have specifically assessed 
host risk factors for acute cardiac events in pneumococcal 
pneumonia. Moreover, the potential link between pneumo-
coccal genotypes (clonal complexes) and cardiac complications 
in humans with pneumococcal CAP has not been explored. 
Nevertheless, a recent study has found an association between 
the development of acute cardiac events and pneumococcal 
serotypes 3 and 9N in 310 patients with invasive pneumococcal 
disease (of whom 60% had CAP) [22]. An association between 
any pneumococcal serotype or clonal complex and cardiac 
events could have important public health implications with re-
gard to the composition of further pneumococcal vaccines.
Here, we aim to assess the host- and pathogen-related fac-
tors, more specifically serotypes and genotypes (clonal com-
plexes), related to a high risk of developing acute cardiac events 
in a large prospective cohort of hospitalized patients with 
pneumococcal CAP.
METHODS
Setting, Patients, and Study Design
This retrospective cohort study was performed at the Bellvitge 
University Hospital, a 750-bed tertiary academic hospital for 
adults in Barcelona, Spain. All nonimmunocompromised pa-
tients aged ≥18 years with pneumococcal CAP who were hos-
pitalized through the emergency room from January 1, 1996, to 
September 30, 2019, were included. Data on all patients were 
prospectively recorded using a computer-assisted protocol. 
Patients with neutropenia, HIV infection, or transplantation 
were not included.
To identify risk factors for acute cardiac events during hos-
pitalization, patients with pneumococcal pneumonia were di-
vided into 2 groups: those who developed acute cardiac events 
(new-onset or worsening cardiac arrhythmias, new-onset or 
worsening congestive heart failure and/or myocardial infarc-
tion) and those without acute cardiac events during hospital 
stay. A  comparison of S.  pneumoniae strains isolated from 
patients with pneumococcal pneumonia and with or without 
acute cardiac events was performed. Local clinical practices 
regarding initial microbiological testing and empirical antibi-
otic therapy are detailed in the Supplementary Data. Serotypes, 
genotypes (clonal complexes), and penicillin susceptibility of 
isolated strains were analyzed.
Patients were seen during their hospital stay by 1 or more 
of the investigators who recorded clinical data, including the 
occurrence of any acute cardiac event, and microbiological 
findings in a computer-assisted protocol (case report form, 
Supplementary Data). Patients were seen at the outpatient clinic 
30 days after hospital discharge.
Patient Consent Statement
The study was approved by the Bellvitge University Hospital 
Ethics Committee. Informed consent was waived because of the 
observational nature of the study and because the analysis used 
anonymous clinical data. The STROBE guidelines were used to 
ensure the reporting of the study (Supplementary Table 1).
Definitions
New-onset or worsening cardiac arrhythmias were considered 
when they were documented by an electrocardiogram (ECG). 
New-onset or worsening congestive heart failure was considered 
when patients fulfilled Framingham criteria [23]. Myocardial 
infarction was defined as the detection of an increase in car-
diac biomarkers (creatine kinase fraction MB and/or troponin) 
with at least 1 of the following manifestations: symptoms of is-
chemia, ECG changes (new ST-T changes or a new left bundle 
branch block), or development of pathological Q waves. Early 
and overall mortality were defined as death due to any cause 
≤48 hours and ≤30 days after hospitalization, respectively. The 
definitions for pneumococcal CAP and other variables are de-
tailed in the Supplementary Data.
Microbiological Studies
S.  pneumoniae was identified using standard microbiological 
procedures. S.  pneumoniae urinary antigen detection was per-
formed with a rapid immunochromatographic assay (BinaxNOW 
Streptococcus pneumoniae, Abbott, Lake Bluff, Illinois, USA). 
Penicillin susceptibility was tested by the microdilution 
method, following the European Committee on Antimicrobial 
Susceptibility Testing methods and criteria (EUCAST).
Serotypes were identified using the Quellung reaction at the 
Spanish Reference Laboratory [24] and/or by conventional pol-
ymerase chain reaction following the methodology described 
by the Centers for Disease Control and Prevention [25]. For 
genotyping all available strains, pulsed-field gel electropho-
resis with multilocus sequence typing (PFGE/MLST) scheme 
was performed following a previously described methodology 
[26]. PFGE patterns were visually compared. Representative 
strains of the main clusters (those accounting for >5 pneumo-
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types (STs) were assigned using the pneumococcal multilocus 
sequence typing website [27]. Unusual serotype–genotype com-
binations were retested.
Statistical Analysis
Categorical variables were presented by the number of cases 
and percentages, and continuous variables by means and SDs or 
medians and interquartile ranges (IQRs). Continuous variables 
were compared using the Student t test or Mann-Whitney U test 
where appropriate. The Fisher exact test or Pearson χ2 test was 
applied to assess the relationship between categorical variables.
To estimate the magnitude of the associations between 
covariates and the development of acute cardiac events, 
multivariable adjusted ORs and their corresponding 95% con-
fidence intervals were computed by logistic regression. A po-
tential set of predictors was prespecified based on the literature. 
The cohort was sampled by bootstrapping with replacement 
1000 times. A model was fitted in each sample using stepwise 
elimination and the Akaike information criterion. Predictors 
retained in more than 70% of the models were considered for 
inclusion in the selected model. Factors included in the model 
are detailed in the Supplementary Data. Comparison of acute 
cardiac event rates between serotypes and clonal complexes was 
carried out taking into account the volume of patients at risk 
and was represented graphically with funnel plots [28]. Using 
the overall acute cardiac event rate as a benchmark, serotypes 
or clonal complexes above or below the benchmark’s confidence 
interval would indicate that the risk observed was significantly 
higher or lower than expected. If the serotypes or clonal com-
plexes were within the benchmark’s confidence interval, this 
would indicate that the risk observed was as expected. Only 
serotypes and genotypes (clonal complexes) isolated in 10 or 
more cases were analyzed. As a general strategy, variables with 
>25% of missing values were not considered. No imputation 
was performed for missing values, and no sensitivity analysis 
was carried out. Whenever possible, 95% confidence intervals 
accompanied point estimators. All analyses were performed 
with a 2-sided significance level of .05 and were conducted with 
R Statistical Software, version 3.6.3 [29].
RESULTS
Over the study period, 1739 consecutive adults with pneumo-
coccal pneumonia were included, of whom 304 (17.5%) devel-
oped 1 or more acute cardiac events during hospitalization. The 
most frequent cardiac complications were arrhythmia (n = 207, 
of which 124 were new-onset atrial fibrillation/flutter), heart 
failure (n = 135, of which 85 were new-onset heart failure), 
and myocardial infarction (n = 23), with the majority of events 
occurring within 48 hours (73.4%) of admission. Details of 
the microbiological methods used to establish the diagnosis 
of pneumococcal pneumonia are shown in the Supplementary 
Table 2. In brief, S. pneumoniae was isolated in 1 or more clin-
ical samples in 983 (56.5%) patients, with the remaining pa-
tients being diagnosed through antigen testing, and 495 (28.5%) 
had pneumococcal bacteremia.
Baseline characteristics of patients with pneumococcal pneu-
monia who developed acute cardiac events and those who did 
not are detailed in Table 1. Patients who developed acute cardiac 
events were significantly older, had more preexisting heart condi-
tions, and had more comorbidities such as stroke, dyslipidemia, 
arterial hypertension, peripheral artery disease, chronic renal 
disease, and chronic obstructive pulmonary disease. They were 
more often receiving oral anticoagulants, antiplatelet therapy, 
statins, beta-blockers, angiotensin-converting enzyme inhibi-
tors or angiotensin II receptor blockers, and diuretics. They 
also had more often pneumococcal bacteremia, a more severe 
presentation with a higher pneumonia severity index (PSI), and 
higher rates of septic shock at admission, hypoalbuminemia, 
and respiratory insufficiency. Patients without acute cardiac 
events were more likely to have received prehospitalization an-
tibiotic treatment for the acute episode of pneumonia, which 
was associated with a lower frequency of bacteremia (13.3% 
vs 30.8%; P < .001), a lower proportion of septic shock at ad-
mission (7.3% vs 13.3%; P < .01), and a lower rate of high-risk 
pneumonia (PSI classes IV and V, 56% vs 65.6%; P = .017). In 
the adjusted multivariate logistic regression analysis, age, preex-
isting heart conditions, pneumococcal bacteremia, septic shock 
at admission, and high-risk pneumonia (PSI classes IV and V) 
were found to be independent risk factors for the development 
of acute cardiac complications in pneumococcal CAP (Table 2).
Regarding pathogen-related factors, among 983 pneumo-
coccal isolates, 872 (88.7%) were serotyped and 742 (75.5%) 
genotyped. A  complete distribution of identified serotypes 
and clonal complexes is detailed in Supplementary Tables 3 
and 4. Serotype 3 was the most common, and it was mainly 
related to clonal complexes CC180 and CC260; the β-lactam-
resistant CC156, which included serotypes 9V and 14, was 
third. A funnel plot analysis (Figure 1) showed a trend toward a 
higher incidence of acute cardiac complications than expected 
with serotype 4, whereas serotypes 6A, 5, and 1 had a lower in-
cidence than expected. The clonal complex CC230 showed a 
trend toward a higher rate of acute cardiac events in the funnel 
plot analysis (Figure  2), whereas the serotype 5–associated 
clonal complex CC289 had a lower incidence than expected. 
No differences in penicillin minimum inhibitory concentration 
were observed between the 2 groups (Supplementary Table 5).
Initial empirical antibiotic treatment and outcomes are 
summarized in Table 3. According to our local guidelines for 
treatment of CAP, combination therapy with β-lactam and 
fluoroquinolone is recommended for severe pneumonia. 
Accordingly, it was associated with a higher rate of septic shock, 
respiratory failure, intensive care unit (ICU) admission, and a 
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was observed in patients who were empirically treated with 
β-lactam and fluoroquinolone combination therapy in the uni-
variate analysis; however, fluoroquionolone exposure (either as 
mono- or combination therapy) was not. Patients with pneu-
mococcal pneumonia with acute cardiac events had a greater 
need for ICU admission, mechanical ventilation, and a longer 
hospital stay. Among the 304 patients with pneumococcal 
pneumonia with acute cardiac events, the 30-day mortality 
was 13.9%, compared with 4.7% among those patients without 
cardiac complications (P = .001). Acute cardiac events were 
Table 2. Adjusted Multivariate Logistic Regression for Acute Cardiac 
Events in 1739 Episodes of Pneumococcal Pneumonia
Variable
Odds Ratio for Acute 
Cardiac Events (95% CI)
P 
Value
Age 1.02 (1–1.03) .009
Preexisting heart disease 3.45 (2.54–4.71) <.001
Pneumococcal bacteremia 2.52 (1.86–3.42) <.001
Septic shock at admission 1.77 (1.21–2.59) .003
High-risk pneumonia (PSI >90 
points, classes IV and V)
2.33 (1.56–3.54) <.001
Abbreviation: PSI, pneumonia severity index.
Table 1. Baseline Characteristics of Patients With Pneumococcal Pneumonia who Developed Acute Cardiac Events and Those who Did Not
Patients (n = 1739)
Pneumococcal Pneumonia With Acute Cardiac 
Events (n = 304), No. (%)
Pneumococcal Pneumonia Without Acute 
Cardiac Events (n = 1435), No. (%) P Value
Mean age (SD), y 73.4 (12.6) 65.8 (17.2) <.001
Age ≥70 y 200/304 (65.8) 710/1435 (49.5) <.001
Female sex 111/304 (36.5) 509/1435 (35.5) .78
Vaccination status
 Influenza vaccine (season) 147/256 (48.4) 628/1328 (43.8) .14
 Pneumococcal vaccination (<5 y) 53/245 (21.6) 233/1296 (18) .21
Current smoker 59/302 (19.5) 407/1431 (28.4) .002
Heavy alcohol consumption 39/302 (12.9) 244/1429 (17.1) .091
Underlying disease
 Chronic obstructive pulmonary disease 115/304 (37.8) 434/1435 (30.2) .012
 Cancer 31/304 (10.2) 120/1435 (8.4) .36
 Chronic renal disease 40/304 (13.2) 110/1435 (7.7) .003
 Chronic liver disease 25/304 (8.2) 122/1435 (8.5) .96
 Dementia 13/304 (4.3) 77/1435 (5.4) .52
 Stroke 36/304 (11.8) 112/1435 (7.8) .029
 Peripheral artery disease 23/284 (7.6) 52/1266 (3.6) .004
 Arterial hypertension 126/288 (43.8) 424/1352 (31.4) <.001
 Diabetes mellitus 80/304 (26.3) 303/1435 (21.1) .056
 Dyslipidemia 75/286 (26.2) 264/1342 (19.7) .017
 Preexisting heart conditions 173/304 (56.9) 344/1435 (24) <.001
 Arrhythmia 94/304 (30.9) 162/1435 (11.3) <.001
 Coronary disease 60/304 (19.7) 120/1435 (8.4) <.001
 Congestive heart failure 71/304 (23.4) 98/1435 (6.8) <.001
Baseline treatment
 Oral anticoagulation 51/281 (18.1) 84/1253 (6.7) <.001
 Antiplatelet therapy 85/283 (30) 267/1266 (21.1) .002
 Statin treatment 61/282 (21.6) 171/1264 (13.5) .001
 Beta-blockers 37/282 (13.1) 101/1266 (7.98) .009
 ACE inhibitor and/or angiotensin II re-
ceptor blocker
88/283 (31.1) 286/1266 (22.6) .003
 Diuretic therapy 105/283 (37.1) 256/1266 (20.2) <.001
Prehospitalization antibiotic treatment 24/287 (8.36) 202/1404 (14.4) .004
Multilobar pneumonia 97/304 (31.9) 389/1435 (27.1) .10
Respiratory insufficiencya 218/304 (71.7) 847/1435 (59) <.001
Pleural effusion 38/304 (12.5) 200/1435 (13.9) .57
Empyema 13/304 (4.28) 79 /1434 (5.5) .47
Septic shock at admission 60/304 (19.7) 162/1432 (11.3) <.001
Hypoalbuminemia (<30 g/L) 129/259 (49.8) 512/1225 (41.8) .021
Pneumococcal bacteremia 121/304 (39.8) 374/1435 (26.1) <0.001
High-risk pneumonia (PSI >90 points, 
classes IV and V)
259/304 (85.2) 866/1433 (60.3) <.001
Abbreviations: ACE, acute cardiac event; PSI, pneumonia severity index.
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independently associated with 30-day mortality (adjusted odds 
ratio, 1.88; 95% CI, 1.11–3.13; P = .017).
DISCUSSION
This retrospective study of a large cohort of patients with pneu-
mococcal pneumonia defined several host factors associated 
with the development of acute cardiac events. We also studied 
a possible link between both pneumococcal serotypes or clonal 
complexes and the risk of developing cardiac complications.
The host factors we found to be independently associated with 
acute cardiac events in pneumococcal pneumonia were older 
age, preexisting heart conditions, pneumococcal bacteremia, 
septic shock at admission, and high-risk pneumonia. A finding 
of interest in our study is the fact that prehospitalization anti-
biotic treatment for the acute episode of pneumococcal pneu-
monia tended to display a protective effect for acute cardiac 
events, although it did not reach statistical significance in the 
multivariate analysis. Interestingly, experimental animal studies 
have shown a significant positive correlation between pneu-
mococcal blood load and cardiac damage [17, 20]. In addition, 
pneumococcal bacteremia has been shown to be an important 
trigger for the development of acute cardiac events in CAP pa-
tients [31]. We found a lower incidence of bacteremia and a less 
severe clinical presentation in patients with prehospitalization 
antibiotic treatment, which may, to some extent at least, explain 
the lower incidence of cardiac complications.
Previous information regarding characteristics of pneu-
mococcal strains and cardiac complications is derived from 2 
studies [20, 22]. An experimental study evaluating not more 
than 6 mice per strain showed that only serotypes able to 
cause high-grade bacteremia, such as serotypes 2, 3, 4, and 
6A, produced cardiac damage [20]. Moreover, for the sero-
types that could invade the heart, the type of cardiac damage 
was strain specific. In addition, a recent study of 310 patients 
with invasive pneumococcal disease, of whom 71 presented 
an acute cardiac event, found an association between sero-
types 3 and 9N [22]. In that study, clonal complexes were not 
analyzed. In contrast, in our study, which included a large 
number of patients, we did not find any significant associ-
ation of serotypes 3 and 9N with acute cardiac events. Our 
study, analyzing serotypes isolated from 872 patients and 
clonal complexes from 742, found a negative trend linking 
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Table 3. Treatment and Outcomes of Pneumococcal Pneumonia in Patients who Developed Acute Cardiac Events and Those who Did Not
Patients (n = 1739)
Pneumococcal Pneumonia With Acute 
Cardiac Events (n = 304), No. (%)
Pneumococcal Pneumonia Without Acute 




 β-lactam monotherapy 131/304 (43.1) 700/1435 (48.8) .082
 β-lactam + macrolide 5/304 (1.6) 32/1435 (2.2) .672
 Fluoroquinolone monotherapy 24/304 (7.9) 140/1435 (9.8) .37
 β-lactam + fluoroquinolone 134/304 (44.1) 525/1435 (36.6) .017
 Fluoroquinolone (alone or any 
combination)
158/304 (52) 669/1435 (46.6) .102
 Macrolide (alone or any combi-
nation)
6/304 (2) 37/1435 (2.6) .68
 Other 10/304 (3.3) 37/1435 (2.6) .62
Door-to-needle antibiotic time, me-
dian (IQRa), h
5 (3.00–8.00) 5 (3.00–7.00) .72
Intensive care unit admission 79/304 (26) 147/1435 (10.2) <.001
Need for mechanical ventilationb 74/304 (24.3) 111/1435 (7.7) <.001
Length of hospital stay, median 
(IQR), d
10 (7.00–18.2) 8 (5.00–11.00) <.001
Early mortality (≤48 h) 8/304 (2.6) 22/1435 (1.71) .24
30-d mortality 42/304 (13.8) 68/1435 (4.7) <.001
Abbreviation: IQR, interquartile range.
aData missing in 482 patients. 
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as 5 (CC289) or 1 (CC306). Moreover, clonal complex CC230 
tended to be associated with a higher incidence of acute car-
diac events. This finding, although not statistically significant 
in the funnel plot, may be clinically relevant. In our study, 
clonal complex CC230 was mainly related to serotypes 19A 
and 24F. Serotype 19A was not associated with acute car-
diac events, suggesting that genetic background, and not 
serotype, could play a major role in these serious complica-
tions. Importantly, while serotype 19A is included in both 
conjugated and polysaccharide pneumococcal vaccines, se-
rotype 24F is not covered by the current vaccines or by any of 
those under development. It is plausible that certain strains 
disproportionally impact individuals who have risk factors 
for ACEs—older age, preexisting heart disease. Multivariate 
analyses that include serotype-specific information should be 
performed in future investigations.
Our finding that CC230 tends to be associated with a 
higher incidence of acute cardiac events is hypothesis-
generating and should be explored in further multicenter 
studies in other geographical areas and including a higher 
number of pneumococcal strains. Our study also opens up 
avenues for further research exploring the association of the 
pneumococcal serotypes and genotypes and long-term risk 
of serious cardiac events.
Despite a number of strengths, our study has some limita-
tions that should be acknowledged. First, the study involved 
a cohort of adults with pneumococcal pneumonia recorded 
over more than 20  years at a single center. This may limit 
the extrapolation of our results to other geographical areas 
where other serotypes and clonal complexes may be more 
prevalent [30]. Second, serotyping and genotyping were not 
performed in all isolates; however, serotypes and genotypes 
were determined in the majority of the 983 isolates (89% and 
76%, respectively). Third, the small number of some sero-
types and clonal complexes limited the analysis of their po-
tential relationship with acute cardiac complications. Lastly, 
worsening of preexisting heart conditions was included as 
an acute cardiac event and may have confounded the results; 
however, analyzing exclusively new-onset arrhythmia, new-
onset heart failures, and myocardial infarction yielded sim-
ilar results.
In summary, acute cardiac events are frequent and confer 
worse clinical outcomes in pneumococcal pneumonia. Although 
CC230 tends to be associated with a higher incidence of acute 
cardiac events, host factors appear to be more important than 
pathogen-related factors for developing these life-threatening 
complications. The host factors defined in this study may help 
identify the patients who require close follow-up including 
heart rhythm monitoring and special care to avoid fluid over-
load, particularly within the first 48 hours of admission. These 
high-risk patients should be the target for urgent preventive in-
tervention strategies.
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the posted materials are not copyedited and are the sole responsibility 
of the authors, so questions or comments should be addressed to the 
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